[go: up one dir, main page]

DK3344287T3 - Anti-survivin-antistoffer til cancerterapi - Google Patents

Anti-survivin-antistoffer til cancerterapi Download PDF

Info

Publication number
DK3344287T3
DK3344287T3 DK16843185.6T DK16843185T DK3344287T3 DK 3344287 T3 DK3344287 T3 DK 3344287T3 DK 16843185 T DK16843185 T DK 16843185T DK 3344287 T3 DK3344287 T3 DK 3344287T3
Authority
DK
Denmark
Prior art keywords
cancer therapy
survivin antibodies
survivin
antibodies
cancer
Prior art date
Application number
DK16843185.6T
Other languages
English (en)
Inventor
Robert A Fenstermaker
Michael J Ciesielski
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of DK3344287T3 publication Critical patent/DK3344287T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16843185.6T 2015-09-04 2016-09-06 Anti-survivin-antistoffer til cancerterapi DK3344287T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562214242P 2015-09-04 2015-09-04
PCT/US2016/050391 WO2017041092A2 (en) 2015-09-04 2016-09-06 Anti-survivin antibodies for cancer therapy

Publications (1)

Publication Number Publication Date
DK3344287T3 true DK3344287T3 (da) 2021-07-19

Family

ID=58188638

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16843185.6T DK3344287T3 (da) 2015-09-04 2016-09-06 Anti-survivin-antistoffer til cancerterapi

Country Status (10)

Country Link
US (3) US10167340B2 (da)
EP (1) EP3344287B1 (da)
JP (1) JP6831836B2 (da)
KR (1) KR102773176B1 (da)
CN (1) CN108883163B (da)
AU (1) AU2016318158B2 (da)
CA (1) CA2997103A1 (da)
DK (1) DK3344287T3 (da)
ES (1) ES2883128T3 (da)
WO (1) WO2017041092A2 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4271411A4 (en) * 2020-12-31 2024-12-18 Health Research, Inc. ANTI-SURVIVIN ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0950103B1 (en) * 1996-11-20 2008-11-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
AU2730801A (en) * 1999-12-21 2001-07-03 Yale University Survivin promotion of angiogenesis
EP1556403A4 (en) * 2002-10-03 2006-06-28 Large Scale Biology Corp ENGINEERING MULTIMERIC PROTEINS
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
DK3332808T3 (da) 2005-03-03 2020-12-14 Immunomedics Inc Humaniserede L243-antistoffer
EP1981912A2 (en) * 2006-01-13 2008-10-22 Irm, Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶(hepcidin)、海帕西啶拮抗劑及使用方法
US8580269B2 (en) 2007-07-19 2013-11-12 Health Research, Inc. Survivin peptides for autoimmune therapies
US7943138B2 (en) 2007-07-19 2011-05-17 Health Research, Inc. Survivin peptides as cancer vaccines
EP2419447B1 (en) * 2009-04-17 2017-08-23 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
WO2014127276A1 (en) * 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Ovarian cancer vaccines and vaccination methods
CN104098696A (zh) * 2013-04-07 2014-10-15 中美华世通生物医药科技(武汉)有限公司 一种抗血管内皮生长因子的单克隆抗体

Also Published As

Publication number Publication date
CN108883163B (zh) 2022-04-15
AU2016318158A1 (en) 2018-04-05
US11773181B2 (en) 2023-10-03
WO2017041092A2 (en) 2017-03-09
US20170066837A1 (en) 2017-03-09
EP3344287A2 (en) 2018-07-11
US20200377613A1 (en) 2020-12-03
ES2883128T3 (es) 2021-12-07
EP3344287B1 (en) 2021-05-26
JP2018529672A (ja) 2018-10-11
WO2017041092A3 (en) 2017-05-11
EP3344287A4 (en) 2019-04-24
AU2016318158B2 (en) 2022-09-15
CA2997103A1 (en) 2017-03-09
US10738129B2 (en) 2020-08-11
JP6831836B2 (ja) 2021-02-17
CN108883163A (zh) 2018-11-23
US20190119398A1 (en) 2019-04-25
KR102773176B1 (ko) 2025-02-27
US10167340B2 (en) 2019-01-01
KR20180042431A (ko) 2018-04-25

Similar Documents

Publication Publication Date Title
IL264023A (en) Nant cancer vaccine
SG10201913631TA (en) Rna for cancer therapy
IL254705B (en) Combined treatment for cancer
HUE046505T2 (hu) Antitestkészítmények daganatkezelésre
KR20180084772A (ko) 암 치료를 위한 조합 치료법
EP3413927A4 (en) CANCER THERAPY
IL260347A (en) Therapeutic antibodies against cd-9
HK1257910A1 (zh) 卵巢癌疫苗
IL259864A (en) Monomaleimide-functionalized platinum compounds for cancer therapy
HK1245120A1 (zh) 用於癌症的新治療
LT3383385T (lt) Melflufeno dozavimo režimas vėžio atveju
EP3310915A4 (en) TUMOR IMMUNOTHERAPY
DK3405212T3 (da) Cancervacciner
DK3317300T3 (da) Bispecifikke antistoffer til anvendelse i kræftimmunterapi
DK3277325T3 (da) Kombinationsimmunterapi for cancer
GB201519734D0 (en) Cancer therapy
DK3344287T3 (da) Anti-survivin-antistoffer til cancerterapi
HK1254687A1 (zh) 用於癌症的聯合療法
IL260988A (en) Ptps-based vaccines against cancer
HRP20210383T8 (hr) Kombinirana terapija za rak
TH1501007353A (th) สารประกอบชนิดใหม่สำหรับการบำบัดโรคมะเร็ง
GB201509493D0 (en) Therapeutic antibody
GB201511609D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy